We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics that may contribute to improvements in global human health. Our 200+ patent portfolio covers next-generation biologic drugs and novel oncology therapeutics and provides protection for our current drug candidates and positions as well as strategic partnership and commercialization opportunities.

Our lead product candidates include ErepoXen™, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and U.S. Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa® and OncoHist™ for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively.

We are currently working together with Shire (LSE: SHP, NASDAQ: SHPG), formerly Baxalta Incorporated, to develop a novel series of polysialylated blood coagulation factors, including a next generation SHP 656 (formerly BAX 826). This collaboration relies on Xenetic's PolyXen technology to conjugate polysialylic acid (PSA) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules.

Shire is one of our largest shareholders as a result of Baxalta having invested $10 million in our common stock in 2014. We have also attracted significant funding and prominent investors from other leading global healthcare companies, including:

Backed by an Experienced Team

Our leadership teams are dedicated to enhancing drugs and improving lives.

Meet our Management Team

Meet our Board of Directors

Meet our Scientific Advisory Board